Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.38 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043327 | 0.81 | NPC1 (0.39) | NPC1L3MBTL1LMNAMMP1MMP2 | |
| SCHEMBL497603 | 0.79 | NPC1 (0.38) | NPC1L3MBTL1LMNAMMP1MMP2 | |
| SCHEMBL5209918 | 0.79 | ALDH1A1 (0.50) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL1395649 | 0.77 | NPC1 (0.54) | NPC1L3MBTL1LMNAMMP1MMP2 | |
| SCHEMBL1630772 | 0.77 | NPC1 (0.54) | NPC1L3MBTL1LMNAMMP1MMP2 | |
| SCHEMBL1022195 | 0.77 | NPC1 (0.54) | NPC1L3MBTL1LMNAMMP1MMP2 | |
| SCHEMBL498179 | 0.75 | CA12 (0.42) | NPC1L3MBTL1LMNAMMP1MMP2 | |
| SCHEMBL8132436 | 0.75 | CA1 (0.46) | LMNACA12CA1CA9CA2 | |
| SCHEMBL5205827 | 0.75 | CA12 (0.50) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL497834 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115175967-B | Ionic liquids for stabilizing viscosity of silicate-based coatings | 巴斯夫欧洲公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-115175967-A | Ionic liquids for stabilizing viscosity of silicate-based coatings | 巴斯夫欧洲公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-2157084-B1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA CO (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8106053-B2 | 5-phenyl-3-pyridazinone derivative | KOWA COMPANY, LTD. | 2012-01-31 | — | — | US | disclosed |
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2157084-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-5300648-A | Analgesics, antiinflammatory agents | SOCIETE ANONYME: ELF SANOFI (FR) | 1994-04-05 | — | — | US | disclosed |
| US-5254595-A | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them | ELF SANOFI (FR) | 1993-10-19 | — | — | US | disclosed |
| US-5236921-A | Administrering for treatment of neutrogenic inflammation of the respiratory trart | SANOFI (FR) | 1993-08-17 | — | — | US | disclosed |
| US-4988718-A | Fungicides for plants | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
| US-4968687-A | AGRICULTURAL FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| EP-0359078-A1 | Substituted heterocyclyl-oximino-pyrazolin-5-ones, method for their preparation and their use as herbicides | BAYER AG (DE) | 1990-03-21 | — | — | EP | disclosed |
| EP-0200915-B1 | AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
| US-4863949-A | CARDIOVASCULAR DISORDER TREATMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280951-A1 | Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates | Roche Diagnostics GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0200915-A1 | Aminopropanol derivatives, process for their preparation, their use and medicines containing them | Roche Diagnostics GmbH (DE) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | SERPINE1, MMP1, PLAT | NPC1 1912/4885L3MBTL1 2490/4885LMNA 715/4885 |
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | NPC1 2944/4885L3MBTL1 2165/4885LMNA 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.